A man has deliberately subjected himself to over 200 venomous snakebites in an ongoing, self-funded effort to improve treatment for snakebite envenomation, a global health crisis that kills tens of thousands and maims hundreds of thousands annually. His unconventional approach highlights critical gaps in current antivenom production and the potential of personalized immunity.
The Problem with Current Antivenom
Snakebites are a significant issue in many parts of the world, with approximately 5 million bites occurring each year, resulting in 138,000 deaths and 400,000+ severe complications. Current antivenoms, though life-saving, rely on injecting horses with venom and harvesting the resulting antibodies. This process carries risks of anaphylactic shock due to the foreign equine proteins involved. Antivenom production is also geographically limited, meaning a treatment effective in one region might fail in another, as venom composition varies.
The Self-Experimentation
Beginning in 2001, the man initiated a series of controlled venom injections, starting at extremely diluted concentrations to build tolerance. He progressively increased doses, eventually enduring full bites from highly venomous species like cobras, taipans, and vipers. His first near-fatal experience – a cobra bite leading to a four-day coma – solidified his commitment. He learned through trial and error, as there are no established protocols for this type of self-experimentation.
Scientific Validation
Over 25 years, he has been studied six times. His unique physiological response to venom has attracted the attention of researchers, including Jacob Glanville at Centivax, who extracted DNA from his B-cells to clone IgG antibodies. Studies in mice have shown these antibodies can neutralize even venoms he has never been exposed to, such as the king cobra’s.
The Breakthrough: Broad-Spectrum Antibodies
The research culminated in a paper published in Cell Press last year, though his name remains off the author list due to the unconventional nature of the study. The findings suggest the possibility of a “universal antivenom” derived from human antibodies, offering a safer and potentially more effective alternative to horse-derived treatments. The man’s dedication underscores that while his methods are extreme, they address a critical need for innovation in venom research.
The path to human-grade antivenom remains long, but the initial results offer a glimmer of hope for reducing the burden of snakebite envenomation worldwide.
